Skip to content

Management of Thyroid Function in Hashimoto's Thyroiditis During Pregnancy

Management of Thyroid Function in Hashimoto's Thyroiditis During Pregnancy: Real-word Experience in a Secondary Endocrine Centre in Italy

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04613323
Enrollment
100
Registered
2020-11-03
Start date
2022-01-01
Completion date
2022-09-01
Last updated
2021-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hashimoto Disease, Pregnancy Related, Thyroid Dysfunction

Brief summary

The management of thyroid function in pregnancy has been object of several guidelines in the last years. Normal thyroid function reduces prenatal and post-natal risks and gestational complaints. Trimester specific reference values of thyroid hormones and thyroid stimulating hormone (TSH) are available for selected geographic population but its are not yet are available in our country. Hashimoto's thyroiditis (HT) is the most frequent autoimmune thyroid disease which can induce thyroid dysfunction, mainly sub-clinical hypothyroidism. Due to the large incidence in women HT and its potential link with thyroid dysfunction this disease could be search and monitored before pregnancy. Anyway a strong recommendation is to test TSH levels in all patients seeking pregnancy at risk for thyroid dysfunction for a history or current symptoms/signs of thyroid dysfunction, known positivity od thyroid autoimmunity or goiter, a history of neck radiation, age \>30 years, diabetes mellitus, previous infertility or pregnant loss, morbid obesity, living in area of moderate-severe iodine deficiency or recent administration of drugs/substance interfering with thyroid function.

Detailed description

The aim of the study was to retrospectively evaluate from 2011 (data of publication of the first American Thyroid Association (ATA) guidelines for thyroid dysfunction in pregnancy) to now medical record of the a secondary level endocrine unit to verify the adherence to guidelines in the management of thyroid function in pregnant women with HT. The investigators search 1. the adherence to clinical and biochemical endocrine evaluations before conception 2. the use (correct/un-correct) of L-T4 intervention and its monitoring 3. the difference in thyroid function control between women with a fix increment of- L-T4 posology (25 mcg/week more for each 2 kg increment in body weight) after the initial L-T4 adjustment or prescription 4. the clinical and biochemical endocrine evaluation 1-2 months after delivery 5. the outcome of pregnancy 6. the e-mail up-to-date survey on current of off-springs health

Interventions

None listed

Sponsors

Centro Diagnostico Priamar
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

Adult HT pregnant women and adult pregnant women with nodular goiter with or whiteout previous known hypothyroidism.

Exclusion criteria

1. significant pre-pregnancy comorbidity including renal failure, severe liver disease, organ transplant, cardiac failure, psychiatric conditions requiring in-patient admission, history of eating disorder. 2. unable to have e-mail address 3. unavailable written consent 4. unable understand Italian language

Design outcomes

Primary

MeasureTime frameDescription
Control of thyroid function in pregnancyThrough study completion, an average of 1 yearThyroid hormones and TSH

Contacts

Primary ContactMassimo Giusti, MD
omsv1416@gmail.com39 3391753444

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026